Trading was heavy with 6,564K shares changing hands on Tuesday. Overall, volume was up 510.11% over the stocks normal daily volume. Short traders are feeling a little more bearish on Advanced Accelerator Applicatio of late if you evaluate the motion in short interest. The stock experienced a rise in short interest of 223.52% between September 29, 2017 and October 13, 2017. Short shares grew from 47,889 to 154,930 over that timeframe.
The following firms have recently changed their position in AAAP. Consonance Capital Management Lp added to its stake by buying 557,652 shares an increase of 42.5% in the quarter. Consonance Capital Management Lp now controls 1,869,507 shares with a value of $72,986,000. The total value of its holdings increased 39.6%. Ubs Group Ag downsized its holdings by shedding 1,465 shares a decrease of 89.9% from 03/31/2017 to 06/30/2017. Ubs Group Ag currently owns 164 shares valued at $6,000. The value of the position overall is down by 90.8%.
Vivo Capital, LLC cut its ownership by shedding 125,000 shares a decrease of 25.8% as of 06/30/2017. Vivo Capital, LLC owns 358,786 shares worth $14,007,000. The value of the position overall is down by 27.4%. Rock Springs Capital Management Lp divested its position by selling 10,000 shares a decrease of 1.2%. Rock Springs Capital Management Lp now holds 840,000 shares valued at $32,794,000. The value of the position overall is down by 3.2%.
Equity analyst JMP Securities raised the price target and upgraded the stock on July 27 changing the price target from $36.00 to $69.00 and moving the rating from “Market Outperform” to “Market Perform”. On July 27 the company was upgraded to “Market Perform” from “Market Outperform” with a current price target of $69.00 by analysts at JMP Securities.
Advanced Accelerator Applications S.A., launched on March 1, 2002, is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. AAA’s diagnostic product is Gluscan, its branded 18-fluorodeoxyglucose (FDG) PET imaging agent. Gluscan assists in the diagnosis of serious medical conditions, primarily in oncology, by assessing glucose metabolism. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications..